Linda Yaccarino, the former CEO of the Elon Musk-owned social media platform X, has a new leadership gig in the weight loss ...

Novo Nordisk’s challenges from both a pharmaceutical giant in Lilly and the low-cost competition from compounded drugs ...

Trade deficit data, Federal Reserve officials' remarks, earnings from Pfizer, Disney, Uber, and additional companies.

Muscle and strength loss in human aging, also known as sarcopenia, can result in trouble with balance and walking, according to the Cleveland Clinic. It’s a condition often linked to obesity, ...

Could popular diabetes and weight loss drugs like Ozempic actually protect your brain from stroke damage, or prevent strokes ...

Eli Lilly (the company behind Mounjaro and Zepbound) just announced impressive phase 3 clinical trial results for a new ...

As use of the popular anti-diabetic and weight-loss drug Ozempic skyrockets, so have concerns about the medication's side ...

Three new studies suggest that Ozempic and related diabetes and weight loss drugs may help protect the brain from strokes.

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

Novo Nordisk (NVO) said Wednesday it will cut costs as it faces increasing competition from Eli Lilly (LLY) and generic versions of its obesity drug Wegovy, with slower growth expected for its ...